nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentamidine—CYP3A4—bone cancer	0.426	1	CbGaD
Pentamidine—CYP4A11—Cisplatin—bone cancer	0.323	0.931	CbGbCtD
Pentamidine—CYP2D6—Doxorubicin—bone cancer	0.0145	0.0419	CbGbCtD
Pentamidine—CYP3A4—Doxorubicin—bone cancer	0.00924	0.0266	CbGbCtD
Pentamidine—AOC1—Tryptophan metabolism—CYP3A4—bone cancer	0.00492	0.0665	CbGpPWpGaD
Pentamidine—CYP4A11—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00315	0.0425	CbGpPWpGaD
Pentamidine—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.00243	0.0328	CbGpPWpGaD
Pentamidine—AOC1—Tryptophan metabolism—MDM2—bone cancer	0.00226	0.0306	CbGpPWpGaD
Pentamidine—CYP4A11—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00182	0.0245	CbGpPWpGaD
Pentamidine—CYP4A11—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.0017	0.023	CbGpPWpGaD
Pentamidine—Ospemifene—CYP3A4—bone cancer	0.00161	1	CrCbGaD
Pentamidine—CYP3A5—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00132	0.0179	CbGpPWpGaD
Pentamidine—CYP1A1—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00125	0.0169	CbGpPWpGaD
Pentamidine—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00115	0.0155	CbGpPWpGaD
Pentamidine—CYP1A1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.00114	0.0154	CbGpPWpGaD
Pentamidine—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.0011	0.0148	CbGpPWpGaD
Pentamidine—CYP4A11—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00104	0.0141	CbGpPWpGaD
Pentamidine—CYP2C19—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00102	0.0138	CbGpPWpGaD
Pentamidine—CYP4A11—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000994	0.0134	CbGpPWpGaD
Pentamidine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—ATF1—bone cancer	0.000974	0.0132	CbGpPWpGaD
Pentamidine—CYP2D6—Codeine and Morphine Metabolism—CYP3A4—bone cancer	0.000945	0.0128	CbGpPWpGaD
Pentamidine—CYP2D6—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00094	0.0127	CbGpPWpGaD
Pentamidine—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000891	0.012	CbGpPWpGaD
Pentamidine—S100B—MyD88 cascade initiated on plasma membrane—ATF1—bone cancer	0.000882	0.0119	CbGpPWpGaD
Pentamidine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—ATF1—bone cancer	0.000873	0.0118	CbGpPWpGaD
Pentamidine—S100B—MyD88 dependent cascade initiated on endosome—ATF1—bone cancer	0.000857	0.0116	CbGpPWpGaD
Pentamidine—CYP3A5—Irinotecan Pathway—CYP3A4—bone cancer	0.000849	0.0115	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 9 (TLR9) Cascade—ATF1—bone cancer	0.000827	0.0112	CbGpPWpGaD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—ATF1—bone cancer	0.000813	0.011	CbGpPWpGaD
Pentamidine—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000797	0.0108	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—ATF1—bone cancer	0.00078	0.0105	CbGpPWpGaD
Pentamidine—CYP4A11—PPAR Alpha Pathway—CDK4—bone cancer	0.000764	0.0103	CbGpPWpGaD
Pentamidine—CYP1A1—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000721	0.00974	CbGpPWpGaD
Pentamidine—S100B—Activated TLR4 signalling—ATF1—bone cancer	0.000702	0.00948	CbGpPWpGaD
Pentamidine—CYP3A5—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000665	0.00898	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—ATF1—bone cancer	0.00066	0.00892	CbGpPWpGaD
Pentamidine—CYP1A1—Estrogen metabolism—CYP3A4—bone cancer	0.000656	0.00886	CbGpPWpGaD
Pentamidine—CYP3A5—Xenobiotics—CYP3A4—bone cancer	0.000638	0.00862	CbGpPWpGaD
Pentamidine—CYP4A11—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000631	0.00852	CbGpPWpGaD
Pentamidine—CYP4A11—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000623	0.00841	CbGpPWpGaD
Pentamidine—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000615	0.00831	CbGpPWpGaD
Pentamidine—CYP3A5—Tamoxifen metabolism—CYP3A4—bone cancer	0.000614	0.00829	CbGpPWpGaD
Pentamidine—CYP1A1—Xenobiotics—CYP3A4—bone cancer	0.000603	0.00815	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—ATF1—bone cancer	0.000588	0.00794	CbGpPWpGaD
Pentamidine—CYP1A1—Tamoxifen metabolism—CYP3A4—bone cancer	0.00058	0.00783	CbGpPWpGaD
Pentamidine—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000578	0.00781	CbGpPWpGaD
Pentamidine—CYP3A5—Metapathway biotransformation—CYP4V2—bone cancer	0.000569	0.00769	CbGpPWpGaD
Pentamidine—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000553	0.00747	CbGpPWpGaD
Pentamidine—CYP2D6—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000543	0.00733	CbGpPWpGaD
Pentamidine—CYP1A1—Metapathway biotransformation—CYP4V2—bone cancer	0.000538	0.00726	CbGpPWpGaD
Pentamidine—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000532	0.00718	CbGpPWpGaD
Pentamidine—CYP4A11—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000512	0.00691	CbGpPWpGaD
Pentamidine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.000493	0.00667	CbGpPWpGaD
Pentamidine—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000493	0.00666	CbGpPWpGaD
Pentamidine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000475	0.00641	CbGpPWpGaD
Pentamidine—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00046	0.00621	CbGpPWpGaD
Pentamidine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000454	0.00613	CbGpPWpGaD
Pentamidine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.00044	0.00594	CbGpPWpGaD
Pentamidine—CYP3A5—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000438	0.00592	CbGpPWpGaD
Pentamidine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000436	0.0059	CbGpPWpGaD
Pentamidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00043	0.00582	CbGpPWpGaD
Pentamidine—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000418	0.00565	CbGpPWpGaD
Pentamidine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000405	0.00547	CbGpPWpGaD
Pentamidine—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000401	0.00541	CbGpPWpGaD
Pentamidine—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000384	0.00519	CbGpPWpGaD
Pentamidine—S100B—TRAF6 Mediated Induction of proinflammatory cytokines—JUN—bone cancer	0.00038	0.00513	CbGpPWpGaD
Pentamidine—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.00037	0.005	CbGpPWpGaD
Pentamidine—S100B—MyD88 cascade initiated on plasma membrane—JUN—bone cancer	0.000343	0.00464	CbGpPWpGaD
Pentamidine—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000343	0.00463	CbGpPWpGaD
Pentamidine—S100B—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—JUN—bone cancer	0.00034	0.0046	CbGpPWpGaD
Pentamidine—CYP1A1—Estrogen Receptor Pathway—JUN—bone cancer	0.00034	0.00459	CbGpPWpGaD
Pentamidine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000339	0.00458	CbGpPWpGaD
Pentamidine—S100B—MyD88 dependent cascade initiated on endosome—JUN—bone cancer	0.000334	0.00451	CbGpPWpGaD
Pentamidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000332	0.00449	CbGpPWpGaD
Pentamidine—CYP4A11—Arachidonic acid metabolism—PTGS2—bone cancer	0.000323	0.00437	CbGpPWpGaD
Pentamidine—S100B—Toll Like Receptor 9 (TLR9) Cascade—JUN—bone cancer	0.000322	0.00435	CbGpPWpGaD
Pentamidine—S100B—MyD88:Mal cascade initiated on plasma membrane—JUN—bone cancer	0.000317	0.00428	CbGpPWpGaD
Pentamidine—S100B—Signaling by ERBB4—KIT—bone cancer	0.000315	0.00426	CbGpPWpGaD
Pentamidine—CYP1A1—Tryptophan metabolism—CYP3A4—bone cancer	0.00031	0.00418	CbGpPWpGaD
Pentamidine—S100B—MyD88-independent cascade—JUN—bone cancer	0.000304	0.00411	CbGpPWpGaD
Pentamidine—Anaphylactic shock—Cisplatin—bone cancer	0.000284	0.00188	CcSEcCtD
Pentamidine—Infection—Cisplatin—bone cancer	0.000282	0.00187	CcSEcCtD
Pentamidine—Hypoglycaemia—Doxorubicin—bone cancer	0.000281	0.00186	CcSEcCtD
Pentamidine—Mood swings—Epirubicin—bone cancer	0.000281	0.00186	CcSEcCtD
Pentamidine—Lethargy—Doxorubicin—bone cancer	0.00028	0.00186	CcSEcCtD
Pentamidine—Cerebrovascular accident—Doxorubicin—bone cancer	0.00028	0.00186	CcSEcCtD
Pentamidine—Thrombocytopenia—Cisplatin—bone cancer	0.000278	0.00184	CcSEcCtD
Pentamidine—Blood creatinine increased—Epirubicin—bone cancer	0.000278	0.00184	CcSEcCtD
Pentamidine—Tachycardia—Cisplatin—bone cancer	0.000277	0.00184	CcSEcCtD
Pentamidine—Asthma—Methotrexate—bone cancer	0.000274	0.00181	CcSEcCtD
Pentamidine—Liver function test abnormal—Epirubicin—bone cancer	0.000274	0.00181	CcSEcCtD
Pentamidine—S100B—Activated TLR4 signalling—JUN—bone cancer	0.000273	0.00369	CbGpPWpGaD
Pentamidine—Dry skin—Epirubicin—bone cancer	0.000272	0.0018	CcSEcCtD
Pentamidine—CYP4A11—Biological oxidations—CYP3A4—bone cancer	0.000272	0.00367	CbGpPWpGaD
Pentamidine—Eosinophilia—Methotrexate—bone cancer	0.000271	0.0018	CcSEcCtD
Pentamidine—Anorexia—Cisplatin—bone cancer	0.000271	0.00179	CcSEcCtD
Pentamidine—Affect lability—Doxorubicin—bone cancer	0.00027	0.00179	CcSEcCtD
Pentamidine—Pancreatitis—Methotrexate—bone cancer	0.000269	0.00178	CcSEcCtD
Pentamidine—Hypotension—Cisplatin—bone cancer	0.000266	0.00176	CcSEcCtD
Pentamidine—Face oedema—Doxorubicin—bone cancer	0.000265	0.00176	CcSEcCtD
Pentamidine—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000265	0.00358	CbGpPWpGaD
Pentamidine—CYP4A11—NRF2 pathway—TGFBR2—bone cancer	0.000265	0.00358	CbGpPWpGaD
Pentamidine—CYP4A11—NRF2 pathway—GSTP1—bone cancer	0.000265	0.00358	CbGpPWpGaD
Pentamidine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000265	0.00357	CbGpPWpGaD
Pentamidine—Gastritis—Epirubicin—bone cancer	0.000263	0.00174	CcSEcCtD
Pentamidine—CYP3A5—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000262	0.00353	CbGpPWpGaD
Pentamidine—Pancytopenia—Methotrexate—bone cancer	0.00026	0.00172	CcSEcCtD
Pentamidine—Mood swings—Doxorubicin—bone cancer	0.00026	0.00172	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000259	0.00171	CcSEcCtD
Pentamidine—Blood creatinine increased—Doxorubicin—bone cancer	0.000257	0.0017	CcSEcCtD
Pentamidine—S100B—Toll Like Receptor 4 (TLR4) Cascade—JUN—bone cancer	0.000257	0.00347	CbGpPWpGaD
Pentamidine—Influenza—Epirubicin—bone cancer	0.000257	0.0017	CcSEcCtD
Pentamidine—Asthma—Epirubicin—bone cancer	0.000257	0.0017	CcSEcCtD
Pentamidine—Neutropenia—Methotrexate—bone cancer	0.000256	0.0017	CcSEcCtD
Pentamidine—Paraesthesia—Cisplatin—bone cancer	0.000255	0.00169	CcSEcCtD
Pentamidine—Eosinophilia—Epirubicin—bone cancer	0.000254	0.00168	CcSEcCtD
Pentamidine—Liver function test abnormal—Doxorubicin—bone cancer	0.000254	0.00168	CcSEcCtD
Pentamidine—Dyspnoea—Cisplatin—bone cancer	0.000253	0.00168	CcSEcCtD
Pentamidine—Dry skin—Doxorubicin—bone cancer	0.000252	0.00167	CcSEcCtD
Pentamidine—Pancreatitis—Epirubicin—bone cancer	0.000252	0.00167	CcSEcCtD
Pentamidine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000251	0.0034	CbGpPWpGaD
Pentamidine—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00025	0.00338	CbGpPWpGaD
Pentamidine—S100B—Signaling by ERBB4—MDM2—bone cancer	0.000248	0.00335	CbGpPWpGaD
Pentamidine—CYP1A1—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000247	0.00334	CbGpPWpGaD
Pentamidine—Decreased appetite—Cisplatin—bone cancer	0.000247	0.00163	CcSEcCtD
Pentamidine—Bronchitis—Epirubicin—bone cancer	0.000247	0.00163	CcSEcCtD
Pentamidine—Drowsiness—Methotrexate—bone cancer	0.000244	0.00162	CcSEcCtD
Pentamidine—Pancytopenia—Epirubicin—bone cancer	0.000244	0.00161	CcSEcCtD
Pentamidine—Gastritis—Doxorubicin—bone cancer	0.000243	0.00161	CcSEcCtD
Pentamidine—Pain—Cisplatin—bone cancer	0.000243	0.00161	CcSEcCtD
Pentamidine—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000242	0.0016	CcSEcCtD
Pentamidine—Renal failure—Methotrexate—bone cancer	0.00024	0.00159	CcSEcCtD
Pentamidine—Neutropenia—Epirubicin—bone cancer	0.00024	0.00159	CcSEcCtD
Pentamidine—Stomatitis—Methotrexate—bone cancer	0.000238	0.00158	CcSEcCtD
Pentamidine—Conjunctivitis—Methotrexate—bone cancer	0.000238	0.00157	CcSEcCtD
Pentamidine—Influenza—Doxorubicin—bone cancer	0.000237	0.00157	CcSEcCtD
Pentamidine—Asthma—Doxorubicin—bone cancer	0.000237	0.00157	CcSEcCtD
Pentamidine—Eosinophilia—Doxorubicin—bone cancer	0.000235	0.00156	CcSEcCtD
Pentamidine—Feeling abnormal—Cisplatin—bone cancer	0.000234	0.00155	CcSEcCtD
Pentamidine—Haematuria—Methotrexate—bone cancer	0.000233	0.00154	CcSEcCtD
Pentamidine—Pancreatitis—Doxorubicin—bone cancer	0.000233	0.00154	CcSEcCtD
Pentamidine—CYP4A11—Biological oxidations—GSTP1—bone cancer	0.000232	0.00314	CbGpPWpGaD
Pentamidine—Hyperglycaemia—Epirubicin—bone cancer	0.000231	0.00153	CcSEcCtD
Pentamidine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00023	0.0031	CbGpPWpGaD
Pentamidine—S100B—Toll-Like Receptors Cascades—JUN—bone cancer	0.000229	0.00309	CbGpPWpGaD
Pentamidine—Drowsiness—Epirubicin—bone cancer	0.000229	0.00151	CcSEcCtD
Pentamidine—Bronchitis—Doxorubicin—bone cancer	0.000228	0.00151	CcSEcCtD
Pentamidine—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000227	0.0015	CcSEcCtD
Pentamidine—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000227	0.00306	CbGpPWpGaD
Pentamidine—Pancytopenia—Doxorubicin—bone cancer	0.000225	0.00149	CcSEcCtD
Pentamidine—Renal failure—Epirubicin—bone cancer	0.000225	0.00149	CcSEcCtD
Pentamidine—Body temperature increased—Cisplatin—bone cancer	0.000225	0.00149	CcSEcCtD
Pentamidine—Neuropathy peripheral—Epirubicin—bone cancer	0.000224	0.00148	CcSEcCtD
Pentamidine—Stomatitis—Epirubicin—bone cancer	0.000223	0.00148	CcSEcCtD
Pentamidine—Conjunctivitis—Epirubicin—bone cancer	0.000222	0.00147	CcSEcCtD
Pentamidine—Neutropenia—Doxorubicin—bone cancer	0.000222	0.00147	CcSEcCtD
Pentamidine—Hepatitis—Methotrexate—bone cancer	0.000219	0.00145	CcSEcCtD
Pentamidine—Haematuria—Epirubicin—bone cancer	0.000218	0.00144	CcSEcCtD
Pentamidine—Pharyngitis—Methotrexate—bone cancer	0.000218	0.00144	CcSEcCtD
Pentamidine—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000217	0.00293	CbGpPWpGaD
Pentamidine—CYP3A5—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000215	0.0029	CbGpPWpGaD
Pentamidine—Sinusitis—Epirubicin—bone cancer	0.000215	0.00142	CcSEcCtD
Pentamidine—Hyperglycaemia—Doxorubicin—bone cancer	0.000214	0.00142	CcSEcCtD
Pentamidine—Drowsiness—Doxorubicin—bone cancer	0.000212	0.0014	CcSEcCtD
Pentamidine—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00021	0.00139	CcSEcCtD
Pentamidine—Hypersensitivity—Cisplatin—bone cancer	0.000209	0.00139	CcSEcCtD
Pentamidine—Bradycardia—Epirubicin—bone cancer	0.000209	0.00138	CcSEcCtD
Pentamidine—Renal failure—Doxorubicin—bone cancer	0.000208	0.00138	CcSEcCtD
Pentamidine—Erythema multiforme—Methotrexate—bone cancer	0.000208	0.00137	CcSEcCtD
Pentamidine—Neuropathy peripheral—Doxorubicin—bone cancer	0.000208	0.00137	CcSEcCtD
Pentamidine—Stomatitis—Doxorubicin—bone cancer	0.000206	0.00137	CcSEcCtD
Pentamidine—Rhinitis—Epirubicin—bone cancer	0.000206	0.00136	CcSEcCtD
Pentamidine—Conjunctivitis—Doxorubicin—bone cancer	0.000206	0.00136	CcSEcCtD
Pentamidine—Hepatitis—Epirubicin—bone cancer	0.000205	0.00136	CcSEcCtD
Pentamidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000205	0.00277	CbGpPWpGaD
Pentamidine—Hypoaesthesia—Epirubicin—bone cancer	0.000204	0.00135	CcSEcCtD
Pentamidine—Asthenia—Cisplatin—bone cancer	0.000204	0.00135	CcSEcCtD
Pentamidine—Pharyngitis—Epirubicin—bone cancer	0.000204	0.00135	CcSEcCtD
Pentamidine—CYP1A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000203	0.00274	CbGpPWpGaD
Pentamidine—Oedema peripheral—Epirubicin—bone cancer	0.000202	0.00134	CcSEcCtD
Pentamidine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000202	0.00273	CbGpPWpGaD
Pentamidine—Haematuria—Doxorubicin—bone cancer	0.000202	0.00134	CcSEcCtD
Pentamidine—Sinusitis—Doxorubicin—bone cancer	0.000199	0.00131	CcSEcCtD
Pentamidine—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000197	0.00267	CbGpPWpGaD
Pentamidine—Chills—Methotrexate—bone cancer	0.000197	0.0013	CcSEcCtD
Pentamidine—Diarrhoea—Cisplatin—bone cancer	0.000194	0.00129	CcSEcCtD
Pentamidine—Erythema multiforme—Epirubicin—bone cancer	0.000194	0.00129	CcSEcCtD
Pentamidine—Bradycardia—Doxorubicin—bone cancer	0.000193	0.00128	CcSEcCtD
Pentamidine—Erythema—Methotrexate—bone cancer	0.000191	0.00126	CcSEcCtD
Pentamidine—Flushing—Epirubicin—bone cancer	0.000191	0.00126	CcSEcCtD
Pentamidine—Rhinitis—Doxorubicin—bone cancer	0.000191	0.00126	CcSEcCtD
Pentamidine—S100B—Innate Immune System—ATF1—bone cancer	0.00019	0.00257	CbGpPWpGaD
Pentamidine—Hepatitis—Doxorubicin—bone cancer	0.00019	0.00126	CcSEcCtD
Pentamidine—Hypoaesthesia—Doxorubicin—bone cancer	0.000189	0.00125	CcSEcCtD
Pentamidine—Pharyngitis—Doxorubicin—bone cancer	0.000189	0.00125	CcSEcCtD
Pentamidine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000188	0.00255	CbGpPWpGaD
Pentamidine—Oedema peripheral—Doxorubicin—bone cancer	0.000187	0.00124	CcSEcCtD
Pentamidine—Dysgeusia—Methotrexate—bone cancer	0.000187	0.00124	CcSEcCtD
Pentamidine—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000186	0.00251	CbGpPWpGaD
Pentamidine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000186	0.00251	CbGpPWpGaD
Pentamidine—Chills—Epirubicin—bone cancer	0.000184	0.00122	CcSEcCtD
Pentamidine—Arrhythmia—Epirubicin—bone cancer	0.000183	0.00121	CcSEcCtD
Pentamidine—Vomiting—Cisplatin—bone cancer	0.000181	0.0012	CcSEcCtD
Pentamidine—Vision blurred—Methotrexate—bone cancer	0.00018	0.00119	CcSEcCtD
Pentamidine—Erythema multiforme—Doxorubicin—bone cancer	0.00018	0.00119	CcSEcCtD
Pentamidine—Rash—Cisplatin—bone cancer	0.000179	0.00119	CcSEcCtD
Pentamidine—Dermatitis—Cisplatin—bone cancer	0.000179	0.00118	CcSEcCtD
Pentamidine—Erythema—Epirubicin—bone cancer	0.000179	0.00118	CcSEcCtD
Pentamidine—Anaemia—Methotrexate—bone cancer	0.000177	0.00117	CcSEcCtD
Pentamidine—Flushing—Doxorubicin—bone cancer	0.000176	0.00117	CcSEcCtD
Pentamidine—Tension—Epirubicin—bone cancer	0.000175	0.00116	CcSEcCtD
Pentamidine—Dysgeusia—Epirubicin—bone cancer	0.000175	0.00116	CcSEcCtD
Pentamidine—Nervousness—Epirubicin—bone cancer	0.000174	0.00115	CcSEcCtD
Pentamidine—Vertigo—Methotrexate—bone cancer	0.000172	0.00114	CcSEcCtD
Pentamidine—Leukopenia—Methotrexate—bone cancer	0.000171	0.00113	CcSEcCtD
Pentamidine—Chills—Doxorubicin—bone cancer	0.000171	0.00113	CcSEcCtD
Pentamidine—Arrhythmia—Doxorubicin—bone cancer	0.00017	0.00112	CcSEcCtD
Pentamidine—S100B—Signaling by ERBB4—EGFR—bone cancer	0.00017	0.00229	CbGpPWpGaD
Pentamidine—Nausea—Cisplatin—bone cancer	0.000169	0.00112	CcSEcCtD
Pentamidine—Vision blurred—Epirubicin—bone cancer	0.000169	0.00112	CcSEcCtD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000167	0.00226	CbGpPWpGaD
Pentamidine—Cough—Methotrexate—bone cancer	0.000167	0.0011	CcSEcCtD
Pentamidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000166	0.00224	CbGpPWpGaD
Pentamidine—Convulsion—Methotrexate—bone cancer	0.000166	0.0011	CcSEcCtD
Pentamidine—Erythema—Doxorubicin—bone cancer	0.000165	0.00109	CcSEcCtD
Pentamidine—Anaemia—Epirubicin—bone cancer	0.000165	0.00109	CcSEcCtD
Pentamidine—CYP4A11—Metabolism—NDUFA12—bone cancer	0.000163	0.0022	CbGpPWpGaD
Pentamidine—Arthralgia—Methotrexate—bone cancer	0.000163	0.00108	CcSEcCtD
Pentamidine—Myalgia—Methotrexate—bone cancer	0.000163	0.00108	CcSEcCtD
Pentamidine—Chest pain—Methotrexate—bone cancer	0.000163	0.00108	CcSEcCtD
Pentamidine—Tension—Doxorubicin—bone cancer	0.000162	0.00107	CcSEcCtD
Pentamidine—Dysgeusia—Doxorubicin—bone cancer	0.000162	0.00107	CcSEcCtD
Pentamidine—Discomfort—Methotrexate—bone cancer	0.000161	0.00106	CcSEcCtD
Pentamidine—Nervousness—Doxorubicin—bone cancer	0.000161	0.00106	CcSEcCtD
Pentamidine—Vertigo—Epirubicin—bone cancer	0.000161	0.00106	CcSEcCtD
Pentamidine—Syncope—Epirubicin—bone cancer	0.00016	0.00106	CcSEcCtD
Pentamidine—Leukopenia—Epirubicin—bone cancer	0.00016	0.00106	CcSEcCtD
Pentamidine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.00016	0.00216	CbGpPWpGaD
Pentamidine—Palpitations—Epirubicin—bone cancer	0.000158	0.00105	CcSEcCtD
Pentamidine—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000158	0.00213	CbGpPWpGaD
Pentamidine—Confusional state—Methotrexate—bone cancer	0.000157	0.00104	CcSEcCtD
Pentamidine—Loss of consciousness—Epirubicin—bone cancer	0.000157	0.00104	CcSEcCtD
Pentamidine—Cough—Epirubicin—bone cancer	0.000156	0.00103	CcSEcCtD
Pentamidine—Anaphylactic shock—Methotrexate—bone cancer	0.000156	0.00103	CcSEcCtD
Pentamidine—Vision blurred—Doxorubicin—bone cancer	0.000156	0.00103	CcSEcCtD
Pentamidine—Convulsion—Epirubicin—bone cancer	0.000155	0.00103	CcSEcCtD
Pentamidine—Infection—Methotrexate—bone cancer	0.000155	0.00103	CcSEcCtD
Pentamidine—Hypertension—Epirubicin—bone cancer	0.000154	0.00102	CcSEcCtD
Pentamidine—Anaemia—Doxorubicin—bone cancer	0.000153	0.00101	CcSEcCtD
Pentamidine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000153	0.00206	CbGpPWpGaD
Pentamidine—Thrombocytopenia—Methotrexate—bone cancer	0.000153	0.00101	CcSEcCtD
Pentamidine—Arthralgia—Epirubicin—bone cancer	0.000152	0.00101	CcSEcCtD
Pentamidine—Myalgia—Epirubicin—bone cancer	0.000152	0.00101	CcSEcCtD
Pentamidine—Chest pain—Epirubicin—bone cancer	0.000152	0.00101	CcSEcCtD
Pentamidine—Anxiety—Epirubicin—bone cancer	0.000152	0.001	CcSEcCtD
Pentamidine—Discomfort—Epirubicin—bone cancer	0.00015	0.000995	CcSEcCtD
Pentamidine—Dry mouth—Epirubicin—bone cancer	0.000149	0.000985	CcSEcCtD
Pentamidine—Vertigo—Doxorubicin—bone cancer	0.000149	0.000984	CcSEcCtD
Pentamidine—Anorexia—Methotrexate—bone cancer	0.000149	0.000984	CcSEcCtD
Pentamidine—Syncope—Doxorubicin—bone cancer	0.000148	0.000982	CcSEcCtD
Pentamidine—Leukopenia—Doxorubicin—bone cancer	0.000148	0.00098	CcSEcCtD
Pentamidine—Confusional state—Epirubicin—bone cancer	0.000147	0.000974	CcSEcCtD
Pentamidine—Palpitations—Doxorubicin—bone cancer	0.000146	0.000968	CcSEcCtD
Pentamidine—Anaphylactic shock—Epirubicin—bone cancer	0.000146	0.000966	CcSEcCtD
Pentamidine—Hypotension—Methotrexate—bone cancer	0.000146	0.000964	CcSEcCtD
Pentamidine—Loss of consciousness—Doxorubicin—bone cancer	0.000145	0.000962	CcSEcCtD
Pentamidine—Infection—Epirubicin—bone cancer	0.000145	0.000959	CcSEcCtD
Pentamidine—Cough—Doxorubicin—bone cancer	0.000144	0.000955	CcSEcCtD
Pentamidine—Shock—Epirubicin—bone cancer	0.000144	0.00095	CcSEcCtD
Pentamidine—Convulsion—Doxorubicin—bone cancer	0.000143	0.000949	CcSEcCtD
Pentamidine—Thrombocytopenia—Epirubicin—bone cancer	0.000143	0.000946	CcSEcCtD
Pentamidine—Hypertension—Doxorubicin—bone cancer	0.000143	0.000945	CcSEcCtD
Pentamidine—Tachycardia—Epirubicin—bone cancer	0.000142	0.000943	CcSEcCtD
Pentamidine—CYP1A1—Tryptophan metabolism—MDM2—bone cancer	0.000142	0.00192	CbGpPWpGaD
Pentamidine—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000142	0.00094	CcSEcCtD
Pentamidine—Insomnia—Methotrexate—bone cancer	0.000141	0.000933	CcSEcCtD
Pentamidine—Chest pain—Doxorubicin—bone cancer	0.000141	0.000932	CcSEcCtD
Pentamidine—Arthralgia—Doxorubicin—bone cancer	0.000141	0.000932	CcSEcCtD
Pentamidine—Myalgia—Doxorubicin—bone cancer	0.000141	0.000932	CcSEcCtD
Pentamidine—Anxiety—Doxorubicin—bone cancer	0.00014	0.000929	CcSEcCtD
Pentamidine—Paraesthesia—Methotrexate—bone cancer	0.00014	0.000927	CcSEcCtD
Pentamidine—Discomfort—Doxorubicin—bone cancer	0.000139	0.000921	CcSEcCtD
Pentamidine—Anorexia—Epirubicin—bone cancer	0.000139	0.000921	CcSEcCtD
Pentamidine—Dyspnoea—Methotrexate—bone cancer	0.000139	0.00092	CcSEcCtD
Pentamidine—Somnolence—Methotrexate—bone cancer	0.000139	0.000917	CcSEcCtD
Pentamidine—S100B—Signaling Pathways—RGS1—bone cancer	0.000138	0.00187	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—GRM4—bone cancer	0.000138	0.00187	CbGpPWpGaD
Pentamidine—Dry mouth—Doxorubicin—bone cancer	0.000138	0.000912	CcSEcCtD
Pentamidine—Dyspepsia—Methotrexate—bone cancer	0.000137	0.000908	CcSEcCtD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000137	0.00185	CbGpPWpGaD
Pentamidine—Hypotension—Epirubicin—bone cancer	0.000136	0.000902	CcSEcCtD
Pentamidine—Confusional state—Doxorubicin—bone cancer	0.000136	0.000901	CcSEcCtD
Pentamidine—Decreased appetite—Methotrexate—bone cancer	0.000136	0.000897	CcSEcCtD
Pentamidine—Anaphylactic shock—Doxorubicin—bone cancer	0.000135	0.000894	CcSEcCtD
Pentamidine—CYP4A11—Metabolism—NT5C3A—bone cancer	0.000135	0.00182	CbGpPWpGaD
Pentamidine—Fatigue—Methotrexate—bone cancer	0.000134	0.00089	CcSEcCtD
Pentamidine—Infection—Doxorubicin—bone cancer	0.000134	0.000888	CcSEcCtD
Pentamidine—Pain—Methotrexate—bone cancer	0.000133	0.000882	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000133	0.00088	CcSEcCtD
Pentamidine—Shock—Doxorubicin—bone cancer	0.000133	0.000879	CcSEcCtD
Pentamidine—Thrombocytopenia—Doxorubicin—bone cancer	0.000132	0.000875	CcSEcCtD
Pentamidine—Insomnia—Epirubicin—bone cancer	0.000132	0.000873	CcSEcCtD
Pentamidine—Tachycardia—Doxorubicin—bone cancer	0.000132	0.000872	CcSEcCtD
Pentamidine—Paraesthesia—Epirubicin—bone cancer	0.000131	0.000867	CcSEcCtD
Pentamidine—Dyspnoea—Epirubicin—bone cancer	0.00013	0.000861	CcSEcCtD
Pentamidine—Somnolence—Epirubicin—bone cancer	0.00013	0.000859	CcSEcCtD
Pentamidine—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000129	0.00175	CbGpPWpGaD
Pentamidine—Anorexia—Doxorubicin—bone cancer	0.000129	0.000852	CcSEcCtD
Pentamidine—Feeling abnormal—Methotrexate—bone cancer	0.000128	0.00085	CcSEcCtD
Pentamidine—Dyspepsia—Epirubicin—bone cancer	0.000128	0.00085	CcSEcCtD
Pentamidine—CYP1A1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000128	0.00173	CbGpPWpGaD
Pentamidine—Gastrointestinal pain—Methotrexate—bone cancer	0.000128	0.000844	CcSEcCtD
Pentamidine—Decreased appetite—Epirubicin—bone cancer	0.000127	0.00084	CcSEcCtD
Pentamidine—Hypotension—Doxorubicin—bone cancer	0.000126	0.000835	CcSEcCtD
Pentamidine—Fatigue—Epirubicin—bone cancer	0.000126	0.000833	CcSEcCtD
Pentamidine—Pain—Epirubicin—bone cancer	0.000125	0.000826	CcSEcCtD
Pentamidine—Constipation—Epirubicin—bone cancer	0.000125	0.000826	CcSEcCtD
Pentamidine—Urticaria—Methotrexate—bone cancer	0.000124	0.00082	CcSEcCtD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000124	0.00167	CbGpPWpGaD
Pentamidine—Body temperature increased—Methotrexate—bone cancer	0.000123	0.000816	CcSEcCtD
Pentamidine—Abdominal pain—Methotrexate—bone cancer	0.000123	0.000816	CcSEcCtD
Pentamidine—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000123	0.000814	CcSEcCtD
Pentamidine—Insomnia—Doxorubicin—bone cancer	0.000122	0.000808	CcSEcCtD
Pentamidine—Paraesthesia—Doxorubicin—bone cancer	0.000121	0.000802	CcSEcCtD
Pentamidine—Dyspnoea—Doxorubicin—bone cancer	0.00012	0.000797	CcSEcCtD
Pentamidine—Feeling abnormal—Epirubicin—bone cancer	0.00012	0.000796	CcSEcCtD
Pentamidine—Somnolence—Doxorubicin—bone cancer	0.00012	0.000794	CcSEcCtD
Pentamidine—S100B—Signaling Pathways—GRM1—bone cancer	0.00012	0.00162	CbGpPWpGaD
Pentamidine—Gastrointestinal pain—Epirubicin—bone cancer	0.000119	0.00079	CcSEcCtD
Pentamidine—Dyspepsia—Doxorubicin—bone cancer	0.000119	0.000787	CcSEcCtD
Pentamidine—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000118	0.00159	CbGpPWpGaD
Pentamidine—Decreased appetite—Doxorubicin—bone cancer	0.000117	0.000777	CcSEcCtD
Pentamidine—Fatigue—Doxorubicin—bone cancer	0.000116	0.00077	CcSEcCtD
Pentamidine—Urticaria—Epirubicin—bone cancer	0.000116	0.000767	CcSEcCtD
Pentamidine—Constipation—Doxorubicin—bone cancer	0.000115	0.000764	CcSEcCtD
Pentamidine—Pain—Doxorubicin—bone cancer	0.000115	0.000764	CcSEcCtD
Pentamidine—Abdominal pain—Epirubicin—bone cancer	0.000115	0.000763	CcSEcCtD
Pentamidine—Body temperature increased—Epirubicin—bone cancer	0.000115	0.000763	CcSEcCtD
Pentamidine—Hypersensitivity—Methotrexate—bone cancer	0.000115	0.00076	CcSEcCtD
Pentamidine—CYP3A5—Biological oxidations—CYP3A4—bone cancer	0.000114	0.00154	CbGpPWpGaD
Pentamidine—CYP3A5—Metapathway biotransformation—CYP3A4—bone cancer	0.000113	0.00152	CbGpPWpGaD
Pentamidine—Asthenia—Methotrexate—bone cancer	0.000112	0.00074	CcSEcCtD
Pentamidine—Feeling abnormal—Doxorubicin—bone cancer	0.000111	0.000736	CcSEcCtD
Pentamidine—S100B—Immune System—ATF1—bone cancer	0.000111	0.0015	CbGpPWpGaD
Pentamidine—Gastrointestinal pain—Doxorubicin—bone cancer	0.00011	0.000731	CcSEcCtD
Pentamidine—Pruritus—Methotrexate—bone cancer	0.00011	0.00073	CcSEcCtD
Pentamidine—S100B—Innate Immune System—KIT—bone cancer	0.000108	0.00146	CbGpPWpGaD
Pentamidine—S100B—Immune System—IL3—bone cancer	0.000108	0.00146	CbGpPWpGaD
Pentamidine—CYP1A1—Biological oxidations—CYP3A4—bone cancer	0.000108	0.00146	CbGpPWpGaD
Pentamidine—Hypersensitivity—Epirubicin—bone cancer	0.000108	0.000712	CcSEcCtD
Pentamidine—Urticaria—Doxorubicin—bone cancer	0.000107	0.00071	CcSEcCtD
Pentamidine—Abdominal pain—Doxorubicin—bone cancer	0.000107	0.000706	CcSEcCtD
Pentamidine—Body temperature increased—Doxorubicin—bone cancer	0.000107	0.000706	CcSEcCtD
Pentamidine—Diarrhoea—Methotrexate—bone cancer	0.000107	0.000706	CcSEcCtD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000106	0.00144	CbGpPWpGaD
Pentamidine—CYP1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000106	0.00144	CbGpPWpGaD
Pentamidine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000105	0.00142	CbGpPWpGaD
Pentamidine—Asthenia—Epirubicin—bone cancer	0.000105	0.000693	CcSEcCtD
Pentamidine—Pruritus—Epirubicin—bone cancer	0.000103	0.000683	CcSEcCtD
Pentamidine—Dizziness—Methotrexate—bone cancer	0.000103	0.000682	CcSEcCtD
Pentamidine—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000101	0.00136	CbGpPWpGaD
Pentamidine—Diarrhoea—Epirubicin—bone cancer	9.98e-05	0.000661	CcSEcCtD
Pentamidine—Hypersensitivity—Doxorubicin—bone cancer	9.95e-05	0.000658	CcSEcCtD
Pentamidine—Vomiting—Methotrexate—bone cancer	9.91e-05	0.000656	CcSEcCtD
Pentamidine—CYP2C8—Biological oxidations—CYP3A4—bone cancer	9.89e-05	0.00134	CbGpPWpGaD
Pentamidine—Rash—Methotrexate—bone cancer	9.83e-05	0.000651	CcSEcCtD
Pentamidine—Dermatitis—Methotrexate—bone cancer	9.82e-05	0.00065	CcSEcCtD
Pentamidine—Headache—Methotrexate—bone cancer	9.77e-05	0.000646	CcSEcCtD
Pentamidine—CYP3A5—Biological oxidations—GSTP1—bone cancer	9.76e-05	0.00132	CbGpPWpGaD
Pentamidine—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	9.75e-05	0.00132	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	9.73e-05	0.00131	CbGpPWpGaD
Pentamidine—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	9.73e-05	0.00131	CbGpPWpGaD
Pentamidine—Asthenia—Doxorubicin—bone cancer	9.69e-05	0.000641	CcSEcCtD
Pentamidine—Dizziness—Epirubicin—bone cancer	9.65e-05	0.000639	CcSEcCtD
Pentamidine—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	9.63e-05	0.0013	CbGpPWpGaD
Pentamidine—Pruritus—Doxorubicin—bone cancer	9.55e-05	0.000632	CcSEcCtD
Pentamidine—Vomiting—Epirubicin—bone cancer	9.28e-05	0.000614	CcSEcCtD
Pentamidine—Nausea—Methotrexate—bone cancer	9.26e-05	0.000613	CcSEcCtD
Pentamidine—Diarrhoea—Doxorubicin—bone cancer	9.24e-05	0.000611	CcSEcCtD
Pentamidine—CYP1A1—Biological oxidations—GSTP1—bone cancer	9.22e-05	0.00125	CbGpPWpGaD
Pentamidine—Rash—Epirubicin—bone cancer	9.2e-05	0.000609	CcSEcCtD
Pentamidine—Dermatitis—Epirubicin—bone cancer	9.19e-05	0.000608	CcSEcCtD
Pentamidine—Headache—Epirubicin—bone cancer	9.14e-05	0.000605	CcSEcCtD
Pentamidine—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	9.1e-05	0.00123	CbGpPWpGaD
Pentamidine—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	9.08e-05	0.00123	CbGpPWpGaD
Pentamidine—Dizziness—Doxorubicin—bone cancer	8.93e-05	0.000591	CcSEcCtD
Pentamidine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	8.82e-05	0.00119	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	8.75e-05	0.00118	CbGpPWpGaD
Pentamidine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	8.7e-05	0.00118	CbGpPWpGaD
Pentamidine—Nausea—Epirubicin—bone cancer	8.67e-05	0.000574	CcSEcCtD
Pentamidine—Vomiting—Doxorubicin—bone cancer	8.58e-05	0.000568	CcSEcCtD
Pentamidine—S100B—Innate Immune System—MDM2—bone cancer	8.54e-05	0.00115	CbGpPWpGaD
Pentamidine—Rash—Doxorubicin—bone cancer	8.51e-05	0.000563	CcSEcCtD
Pentamidine—Dermatitis—Doxorubicin—bone cancer	8.51e-05	0.000563	CcSEcCtD
Pentamidine—Headache—Doxorubicin—bone cancer	8.46e-05	0.00056	CcSEcCtD
Pentamidine—CYP2C8—Biological oxidations—GSTP1—bone cancer	8.45e-05	0.00114	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—SMO—bone cancer	8.44e-05	0.00114	CbGpPWpGaD
Pentamidine—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	8.34e-05	0.00113	CbGpPWpGaD
Pentamidine—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	8.19e-05	0.00111	CbGpPWpGaD
Pentamidine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	8.12e-05	0.0011	CbGpPWpGaD
Pentamidine—Nausea—Doxorubicin—bone cancer	8.02e-05	0.000531	CcSEcCtD
Pentamidine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	8e-05	0.00108	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	7.89e-05	0.00107	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—GNA11—bone cancer	7.71e-05	0.00104	CbGpPWpGaD
Pentamidine—CYP2C19—Biological oxidations—GSTP1—bone cancer	7.55e-05	0.00102	CbGpPWpGaD
Pentamidine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	7.44e-05	0.00101	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—JUN—bone cancer	7.42e-05	0.001	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—ATF1—bone cancer	7.17e-05	0.000969	CbGpPWpGaD
Pentamidine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	7e-05	0.000946	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—IL3—bone cancer	6.99e-05	0.000945	CbGpPWpGaD
Pentamidine—CYP2D6—Biological oxidations—GSTP1—bone cancer	6.94e-05	0.000938	CbGpPWpGaD
Pentamidine—CYP1A2—Biological oxidations—CYP3A4—bone cancer	6.88e-05	0.000929	CbGpPWpGaD
Pentamidine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	6.85e-05	0.000925	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—NDUFA12—bone cancer	6.84e-05	0.000924	CbGpPWpGaD
Pentamidine—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	6.78e-05	0.000916	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—NDUFA12—bone cancer	6.46e-05	0.000873	CbGpPWpGaD
Pentamidine—S100B—Immune System—KIT—bone cancer	6.31e-05	0.000853	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	6.2e-05	0.000838	CbGpPWpGaD
Pentamidine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	6.2e-05	0.000838	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TGFBR2—bone cancer	5.98e-05	0.000808	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—NDUFA12—bone cancer	5.93e-05	0.0008	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—ENO2—bone cancer	5.91e-05	0.000799	CbGpPWpGaD
Pentamidine—CYP1A2—Biological oxidations—GSTP1—bone cancer	5.88e-05	0.000794	CbGpPWpGaD
Pentamidine—S100B—Innate Immune System—EGFR—bone cancer	5.83e-05	0.000788	CbGpPWpGaD
Pentamidine—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	5.8e-05	0.000783	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—NT5C3A—bone cancer	5.67e-05	0.000766	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—IGF1R—bone cancer	5.63e-05	0.00076	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—DHFR—bone cancer	5.48e-05	0.000741	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—NT5C3A—bone cancer	5.36e-05	0.000723	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—NDUFA12—bone cancer	5.29e-05	0.000714	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—GNA11—bone cancer	5.13e-05	0.000692	CbGpPWpGaD
Pentamidine—S100B—Immune System—MDM2—bone cancer	4.97e-05	0.000672	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—NT5C3A—bone cancer	4.91e-05	0.000663	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—NDUFA12—bone cancer	4.86e-05	0.000657	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—CYP3A4—bone cancer	4.65e-05	0.000628	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.62e-05	0.000625	CbGpPWpGaD
Pentamidine—CYP3A4—Biological oxidations—GSTP1—bone cancer	4.54e-05	0.000613	CbGpPWpGaD
Pentamidine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	4.48e-05	0.000605	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—NT5C3A—bone cancer	4.38e-05	0.000592	CbGpPWpGaD
Pentamidine—S100B—Immune System—JUN—bone cancer	4.32e-05	0.000584	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—NDUFA12—bone cancer	4.12e-05	0.000557	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—KIT—bone cancer	4.08e-05	0.000551	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—NT5C3A—bone cancer	4.03e-05	0.000545	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—GSTP1—bone cancer	3.97e-05	0.000537	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—BRAF—bone cancer	3.84e-05	0.000518	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—NT5C3A—bone cancer	3.41e-05	0.000461	CbGpPWpGaD
Pentamidine—S100B—Immune System—EGFR—bone cancer	3.4e-05	0.000459	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—MDM2—bone cancer	3.21e-05	0.000434	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—NDUFA12—bone cancer	3.18e-05	0.00043	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—JUN—bone cancer	2.79e-05	0.000377	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—MMP9—bone cancer	2.72e-05	0.000367	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—NT5C3A—bone cancer	2.64e-05	0.000356	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—ENO2—bone cancer	2.48e-05	0.000335	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—ENO2—bone cancer	2.35e-05	0.000317	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—DHFR—bone cancer	2.3e-05	0.000311	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—EGFR—bone cancer	2.2e-05	0.000297	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—DHFR—bone cancer	2.18e-05	0.000294	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—GNA11—bone cancer	2.15e-05	0.000291	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—ENO2—bone cancer	2.15e-05	0.000291	CbGpPWpGaD
Pentamidine—CYP4A11—Metabolism—PTGS2—bone cancer	2.06e-05	0.000278	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—GNA11—bone cancer	2.03e-05	0.000275	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—DHFR—bone cancer	2e-05	0.00027	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—CYP3A4—bone cancer	1.95e-05	0.000264	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—ENO2—bone cancer	1.92e-05	0.000259	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—GNA11—bone cancer	1.86e-05	0.000252	CbGpPWpGaD
Pentamidine—S100B—Signaling Pathways—TP53—bone cancer	1.84e-05	0.000249	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—CYP3A4—bone cancer	1.84e-05	0.000249	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.83e-05	0.000248	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—DHFR—bone cancer	1.78e-05	0.000241	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—ENO2—bone cancer	1.77e-05	0.000239	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—CYP3A4—bone cancer	1.69e-05	0.000228	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.68e-05	0.000227	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—GSTP1—bone cancer	1.67e-05	0.000226	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—GNA11—bone cancer	1.66e-05	0.000225	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—DHFR—bone cancer	1.64e-05	0.000221	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—GSTP1—bone cancer	1.58e-05	0.000213	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—GNA11—bone cancer	1.53e-05	0.000207	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—CYP3A4—bone cancer	1.51e-05	0.000204	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.5e-05	0.000203	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—ENO2—bone cancer	1.5e-05	0.000202	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—GSTP1—bone cancer	1.45e-05	0.000195	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—CYP3A4—bone cancer	1.39e-05	0.000187	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—DHFR—bone cancer	1.39e-05	0.000187	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—GNA11—bone cancer	1.3e-05	0.000175	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—GSTP1—bone cancer	1.29e-05	0.000174	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—GSTP1—bone cancer	1.19e-05	0.00016	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—CYP3A4—bone cancer	1.18e-05	0.000159	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.17e-05	0.000158	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—ENO2—bone cancer	1.15e-05	0.000156	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—DHFR—bone cancer	1.07e-05	0.000145	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—GSTP1—bone cancer	1.01e-05	0.000136	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—GNA11—bone cancer	1e-05	0.000135	CbGpPWpGaD
Pentamidine—CYP3A5—Metabolism—PTGS2—bone cancer	8.65e-06	0.000117	CbGpPWpGaD
Pentamidine—CYP1A1—Metabolism—PTGS2—bone cancer	8.17e-06	0.00011	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—GSTP1—bone cancer	7.76e-06	0.000105	CbGpPWpGaD
Pentamidine—CYP2C8—Metabolism—PTGS2—bone cancer	7.49e-06	0.000101	CbGpPWpGaD
Pentamidine—CYP2C19—Metabolism—PTGS2—bone cancer	6.69e-06	9.03e-05	CbGpPWpGaD
Pentamidine—CYP2D6—Metabolism—PTGS2—bone cancer	6.15e-06	8.31e-05	CbGpPWpGaD
Pentamidine—CYP1A2—Metabolism—PTGS2—bone cancer	5.21e-06	7.04e-05	CbGpPWpGaD
Pentamidine—CYP3A4—Metabolism—PTGS2—bone cancer	4.02e-06	5.43e-05	CbGpPWpGaD
